Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. / Larsen, Signe Benzon; Brasso, Klaus; Iversen, Peter; Christensen, Jane; Christiansen, Michael; Carlsson, Sigrid; Lilja, Hans; Friis, Søren; Tjønneland, Anne; Dalton, Susanne Oksbjerg.
In: European Journal of Cancer, 16.05.2013.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort
AU - Larsen, Signe Benzon
AU - Brasso, Klaus
AU - Iversen, Peter
AU - Christensen, Jane
AU - Christiansen, Michael
AU - Carlsson, Sigrid
AU - Lilja, Hans
AU - Friis, Søren
AU - Tjønneland, Anne
AU - Dalton, Susanne Oksbjerg
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2013/5/16
Y1 - 2013/5/16
N2 - AIM: Although prostate-specific antigen (PSA) screening reduces mortality from prostate cancer, substantial over-diagnosis and subsequent overtreatment are concerns. Early screening of men for PSA may serve to stratify the male population by risk of future clinical prostate cancer. METHODS AND MATERIAL: Case-control study nested within the Danish 'Diet, Cancer and Health' cohort of 27,179 men aged 50-64 at enrolment. PSA measured in serum collected at cohort entry in 1993-1997 was used to evaluate prostate cancer risk diagnosed up to 14years after. We identified 911 prostate cancer cases in the Danish Cancer Registry through 31st December 2007 1:1 age-matched with cancer-free controls. Aggressive cancer was defined as ⩾T3 or Gleason score ⩾7 or N1 or M1. Statistical analyses were based on conditional logistic regression with age as underlying time axis. RESULTS: Total PSA and free-to-total PSA ratio at baseline were strongly associated with prostate cancer risk up to 14years later. PSA was grouped in quintiles and free-to-total PSA ratio divided in three risk groups. The incidence rate ratio for prostate cancer was 150 (95% confidence interval, 72-310) among men with a total PSA in the highest quintile (>5.1ng/ml) compared to the lowest (
AB - AIM: Although prostate-specific antigen (PSA) screening reduces mortality from prostate cancer, substantial over-diagnosis and subsequent overtreatment are concerns. Early screening of men for PSA may serve to stratify the male population by risk of future clinical prostate cancer. METHODS AND MATERIAL: Case-control study nested within the Danish 'Diet, Cancer and Health' cohort of 27,179 men aged 50-64 at enrolment. PSA measured in serum collected at cohort entry in 1993-1997 was used to evaluate prostate cancer risk diagnosed up to 14years after. We identified 911 prostate cancer cases in the Danish Cancer Registry through 31st December 2007 1:1 age-matched with cancer-free controls. Aggressive cancer was defined as ⩾T3 or Gleason score ⩾7 or N1 or M1. Statistical analyses were based on conditional logistic regression with age as underlying time axis. RESULTS: Total PSA and free-to-total PSA ratio at baseline were strongly associated with prostate cancer risk up to 14years later. PSA was grouped in quintiles and free-to-total PSA ratio divided in three risk groups. The incidence rate ratio for prostate cancer was 150 (95% confidence interval, 72-310) among men with a total PSA in the highest quintile (>5.1ng/ml) compared to the lowest (
U2 - 10.1016/j.ejca.2013.04.015
DO - 10.1016/j.ejca.2013.04.015
M3 - Journal article
C2 - 23684783
JO - European Journal of Cancer, Supplement
JF - European Journal of Cancer, Supplement
SN - 0959-8049
ER -
ID: 48469545